Skip to main content
Fig. 2 | BMC Pharmacology and Toxicology

Fig. 2

From: Impact of matrix metalloproteinase 9 rs3918242 genetic variant on lipid-lowering efficacy of simvastatin therapy in Chinese patients with coronary heart disease

Fig. 2

Concentrations of MMP9 and LDL-C in the blood, and percentage of concentration reduction in CHD patients and control subjects before and after simvastatin treatment. a Plasma MMP9 concentration in CHD patients before and after simvastatin treatment (the left graph), and the percentage of plasma MMP9 concentration reduction in CHD. b Serum concentration of LDL-C in CHD patients before and after simvastatin treatment (the left graph), and the percentage of serum LDL-C concentration reduction in CHD. Error Bars represent 95% confident interval (95% CI). n = 188 subjects with CC, 69 subjects with CT and 7 subjects with TT genotype. *P <0.05, by One-Way ANOVA followed with Bonferroni pairwise test

Back to article page

BMC Pharmacology and Toxicology

ISSN: 2050-6511

Contact us